Hospital
Medical University Hospital Authority
Medical University Hospital Authority was paid $4.53M by Medicaid between Aug 2021 and Dec 2024, across 152 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 18% of everything it billed.
33Billing provider infoMEDICAL UNIVERSITY HOSPITAL AUTHORITY
COLUMBIA, SC 29204
COLUMBIA, SC 29204
33aNPI1558937474assigned 06/01/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.53M
24GClaims186,752
24DCodes billed152
24AFirst – last monthAug 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#53 of 115
Median peer was paid$2.47M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RAE, KARYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 11,630 | $297K | |
| 2022 | 51,418 | $1.39M | |
| 2023 | 62,952 | $1.63M | |
| 2024incomplete | 60,752 | $1.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 18% | 10,499 | 9,189 | $826K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 17% | 4,191 | 2,635 | $784K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 5,416 | 4,996 | $552K |
| 80048 | Basic metabolic panel (calcium, ionized) | 9.3% | 6,698 | 5,272 | $422K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 8.5% | 3,844 | 3,610 | $385K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.9% | 9,384 | 8,555 | $222K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.6% | 1,382 | 1,294 | $117K |
| 81001 | 1.8% | 4,606 | 4,228 | $81K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 1,437 | 1,252 | $80K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 11,470 | 9,090 | $80K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 2,822 | 2,298 | $78K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.5% | 6,096 | 5,597 | $69K |
140 more codes
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.4% | 431 | $61K |
| 82947 | 1.3% | 1,960 | $59K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 1,142 | $58K |
| 81025 | 1.1% | 3,062 | $49K | |
| 81003 | 1.0% | 3,018 | $45K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,352 | $40K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 876 | $34K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,186 | $27K |
| 93970 | <1% | 205 | $25K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 772 | $23K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 223 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 152 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,250 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,989 | $19K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,134 | $18K |
| 73560 | <1% | 476 | $18K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,391 | $16K |
| 93017 | <1% | 522 | $15K | |
| 99285 | Emergency room visit (most serious) | <1% | 3,630 | $14K |
| 93458 | <1% | 509 | $13K | |
| 86780 | <1% | 632 | $13K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 55 | $13K |
| 80061 | Lipid panel | <1% | 2,657 | $11K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 148 | $9K |
| C1769 | Guide wire | <1% | 1,074 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 664 | $9K |
| 87077 | <1% | 446 | $8K | |
| 73030 | <1% | 187 | $8K | |
| 86900 | <1% | 87 | $8K | |
| 93971 | <1% | 57 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 756 | $7K |
| 96376 | <1% | 367 | $6K | |
| 71250 | <1% | 39 | $6K | |
| 87210 | <1% | 40 | $6K | |
| 93880 | <1% | 126 | $6K | |
| 84702 | <1% | 154 | $6K | |
| 84484 | <1% | 4,327 | $6K | |
| 73610 | <1% | 72 | $6K | |
| 85027 | <1% | 2,714 | $6K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,055 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 974 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 24 | $5K |
| 85610 | <1% | 1,558 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 801 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,205 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,594 | $3K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,037 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 976 | $3K |
| 80051 | <1% | 31 | $3K | |
| 73130 | <1% | 47 | $3K | |
| 73630 | <1% | 46 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,729 | $2K |
| 83735 | <1% | 4,653 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 988 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 355 | $2K |
| 83605 | <1% | 721 | $2K | |
| 72100 | <1% | 69 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,134 | $2K |
| 82607 | <1% | 315 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,714 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14 | $2K |
| 86803 | <1% | 629 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 65 | $2K |
| 83880 | <1% | 1,506 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,824 | $1K |
| 80197 | <1% | 495 | $1K | |
| A9270 | Non-covered item or service | <1% | 941 | $1K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 237 | $1K |
| 82043 | <1% | 257 | $1K | |
| 83690 | <1% | 2,722 | $975.45 | |
| 84439 | <1% | 201 | $963.25 | |
| 82728 | <1% | 271 | $872.88 | |
| 86706 | <1% | 37 | $797.47 | |
| 84703 | <1% | 554 | $785.59 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 131 | $682.89 |
| 82570 | <1% | 977 | $655.82 | |
| 94010 | <1% | 14 | $603.28 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 60 | $597.97 |
| 83540 | <1% | 457 | $575.60 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 327 | $558.28 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 87 | $427.99 |
| 93922 | <1% | 12 | $422.07 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,278 | $410.69 |
| 85379 | <1% | 849 | $402.59 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 635 | $355.69 |
| 84156 | <1% | 553 | $352.92 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 979 | $185.92 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,113 | $122.05 |
| 87040 | <1% | 105 | $117.72 | |
| 82746 | <1% | 127 | $114.79 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 924 | $110.90 |
| 87799 | <1% | 31 | $39.44 | |
| 86140 | <1% | 64 | $35.46 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 115 | $30.36 |
| 88304 | <1% | 14 | $26.77 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 254 | $25.11 |
| 84100 | <1% | 1,207 | $13.83 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 685 | $13.31 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,477 | $8.11 |
| 99152 | <1% | 826 | $6.66 | |
| 82248 | <1% | 102 | $2.08 | |
| 85651 | <1% | 13 | $1.26 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 166 | $0.00 |
| 87186 | 0% | 216 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 432 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 327 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 143 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 159 | $0.00 |
| 82565 | 0% | 32 | $0.00 | |
| 85347 | 0% | 127 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 47 | $0.00 |
| 83970 | 0% | 40 | $0.00 | |
| 94729 | 0% | 14 | $0.00 | |
| 84520 | 0% | 31 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 40 | $0.00 |
| 94726 | 0% | 16 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 17 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 31 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 17 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,102 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 334 | $0.00 |
| 83550 | 0% | 202 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 354 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 54 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 611 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,681 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 206 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 501 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 192 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 115 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 147 | $0.00 |
| 85730 | 0% | 1,070 | $0.00 | |
| 82550 | 0% | 12 | $0.00 | |
| 86901 | 0% | 87 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 48 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 103 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 55 | $0.00 |
| 87340 | 0% | 53 | $0.00 | |
| 80320 | 0% | 15 | $0.00 | |
| 82077 | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAE, KARYN (CHIEF)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.